Idarubicin Hydrochloride

Phase 2Small molecule

Idarubicin Hydrochloride is one of 98 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Induction TherapyRecruiting

Relapsed or RefractoryRecruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Induction TherapyPhase 2

Recruiting

Relapsed or RefractoryPhase 2

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 5

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 6

Vepesid

AAvyxa

Phase 3

52 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 9

Cellcept

Roche

Phase 3

10 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Acute Myeloid Leukemia

NCT04214249

Phase 2Recruiting

Relapsed or Refractory

NCT06316960

Q4 2029

Phase 2Recruiting

Induction Therapy

NCT06221683

Q3 2031

Phase 1Recruiting

Acute Myeloid Leukemia

NCT07059975

Q1 2034

Phase 2Recruiting

Acute Myeloid Leukemia

NCT05955261

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia4 trials

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04214249·49 enrolled

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04190550·24 enrolled

A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05955261·70 enrolled

Show 1 more trial

UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML: A Pilot Trial

Recruiting·JJoanna Yi·Phase 1·NCT07059975·36 enrolled

Relapsed or Refractory1 trial

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Recruiting·—·Phase 2·NCT06316960·50 enrolled

Myelodysplastic Syndrome1 trial

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02029950·50 enrolled

Induction Therapy1 trial

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Recruiting·—·Phase 2·NCT06221683·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Idarubicin Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Idarubicin Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Idarubicin Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Idarubicin Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2029

Q3 2031

Q1 2034

Trials by Indication[1]

Acute Myeloid Leukemia4 trials

Relapsed or Refractory1 trial

Myelodysplastic Syndrome1 trial

Induction Therapy1 trial

References

Drug Info

Quick Facts

Related News